Climb Bio (CLYM) Stock Forecast: StockMap's 2-Week Call
CLYM stock forecast: StockMap's model makes no two-week call on Climb Bio after the Nov 19 close: its evidence is split, 6 reasons for and 9 against. Too few two-week windows graded to judge yet.
Climb Bio last closed at $9.28, -0.22% on the session.
Against the IVW growth benchmark the position is +2.11% over the forecast window.
Climb Bio's market cap is $545.06M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -13 (too close to call).
Where CLYM sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 6 bullish and 9 bearish.
Agreement across those insights is 60%.
6 daily calls for CLYM so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Climb Bio in the 23rd percentile on return on equity, where 100 is best.
Climb Bio is classified under Health Care / Biotechnology.
StockMap tracks Climb Bio as the 166th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Climb Bio ranks 115th of 394 in the group, against a group median of -0.27.